NEWS

Impactful technology

AUGUST 2020

 

FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test.

JULY 2020

 

HelixBind awarded $3M Grant from NIH for New Rapid Test for the Early Detection of Lyme Disease.

JUNE 2020

 

HelixBind awarded $3M Grant from NIH and expands Clinical Advisory Board to accelerate development of its diagnostic platform for invasive infections.

December 2019

 

HelixBind awarded $4M of additional funding by CARB-X to continue development of RaPID diagnostic platform.

MARCH 2018

 

HelixBind awarded up to $2M from CARB- X to combat the rise of antimicrobial resistant pathogens.

SEPTEMBER 2017

HelixBind closes $3M in Series-A financing

AUGUST 2017

HelixBind awarded a $2M Phase II SBIR from the National Institutes of Health (NIH) to further development of a culture-free, sample-to-answer test for detecting and identifying microbial pathogens prevalent in neonatal sepsis.

APRIL 2017

USPTO issues HelixBind patent US 14/402,028 covering methods and compositions of matter for diagnosing sepsis

AUGUST 2016

HelixBind awarded a $2.4M Direct-to-Phase II SBIR from the National Institutes of Health (NIH) to automate its sample-to-answer test for discriminating among bacterial pathogens

MARCH 2016

HelixBind published its work, completed in collaboration with Tufts Medical Center and Sloan Memorial Kettering Cancer Center demonstrating successful implementation of its novel sample-to-answer Core Pathogen Identification (C/PID) platform for identifying bloodstream infections directly from patient specimens in under 2.5 hours.

JULY 2015

HelixBind awarded $1.5M Phase II SBIR from the National Institutes of Health (NIH)

MARCH 2014

HelixBind closes $1.65M seed financing

Together we can improve outcomes, save lives, and reduce the spread of antimicrobial resistance.